Mirati Ther

MRTX

NASDAQ. Currency in USD

41.75 -2.10 ( -4.79% )

Real time prices: December 09

Market Cap.
2.40B
Beta (5Y monthly)
0.88
Price/Earnings
-
EPS (TTM)
-13.39
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
4.51M
1y Target Est.
115.69
Day's Range
39.55
-
43.20
52 Week's Range
32.96
-
154.17

Historical Summary

Performance
EPS growth
Share Buybacks

About Mirati Ther

Sector
Healthcare
Industry
Biotechnology
Website
https://www.mirati.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
55.26M
Employees
413
Address
3545 Cray Court, San Diego, CA, United States, 92121
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Latest news

BMO Capital Downgrades Mirati Therapeutics: Here's What You Need To Know
BMO Capital Downgrades Mirati Therapeutics: Here's What You Need To Know

BMO Capital downgraded its rating of Mirati Therapeutics (NASDAQ:MRTX) to Market Perform with a price...
By Benzinga - 1 day ago

Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?
Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 1 day ago

What 10 Analyst Ratings Have To Say About Mirati Therapeutics
What 10 Analyst Ratings Have To Say About Mirati Therapeutics

Over the past 3 months, 10 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX)...
By Benzinga - 1 day ago

Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday

U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here...
By Benzinga - 1 day ago

Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday

Goldman Sachs raised Lowe's Companies, Inc. (NYSE: LOW) price target from $241 to $246. ....
By Benzinga - 1 day ago

Where Mirati Therapeutics Stands With Analysts
Where Mirati Therapeutics Stands With Analysts

Analysts have provided the following ratings for Mirati Therapeutics (NASDAQ:MRTX) within the last quarter: Bullish...
By Benzinga - 1 day ago

Why Shares of Mirati Therapeutics Fell Wednesday
Why Shares of Mirati Therapeutics Fell Wednesday

The company presented phase 2 data from its non-small cell lung cancer therapy.
By The Motley Fool - 2 days ago